arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

download Export Data

Advanced Biomed Inc.

ADVB

$6.62 ▼ -0.92 (-12.27%) at close

12 Visible periods

15 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Advanced Biomed Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $8.5M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC —

FCF / Share $-0.19 ↘

Trailing P/E —

Price / Book 1.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

12-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-488.94K

↑ +64.7% —

FCF / Share Free cash flow per share

$-0.19

↑ +94.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q3 FY2026 Mar 31, 2026 10-Q ↗	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Oct 15, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q3 FY2023 May 16, 2023 10-Q ↗
EPS Growth YoY (%)	71.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	-100.0% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	N/M	-2600.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-400.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	64.7% Excellent ↑ Excellent Improving Year-over-year change in net income	N/M	-45.7% Weak ↑ Weak Improving Year-over-year change in net income	13.3% Fair ↑ Fair Improving Year-over-year change in net income	-31.0% Weak Weak Year-over-year change in net income	-524.7% Weak Weak Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	94.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	42.9% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-1039.2% Weak Weak Year-over-year change in free cash flow	—	-6000.5% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q3 FY2026 Mar 31, 2026 10-Q ↗	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Oct 15, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q3 FY2023 May 16, 2023 10-Q ↗
FCF / Net Income (x)	0.49x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	-0.08x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.58x Excellent ↓ Excellent Declining Free cash flow relative to reported net income Optimal: > 1x	2.23x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	2.47x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.19x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.65x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.03x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 1 metrics

Metric	Q3 FY2026 Mar 31, 2026 10-Q ↗	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Oct 15, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q3 FY2023 May 16, 2023 10-Q ↗
Return on Common Equity (%) (%)	-5.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-135%)	72.3% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+382%)	-12.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-186%)	-20.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-235%)	-33.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-323%)	-146.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1078%)	-24.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-262%)	-48.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-424%)	212.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1315%)	-73.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-592%)	—	—

📊 What does each share earn? 5 metrics

Metric	Q3 FY2026 Mar 31, 2026 10-Q ↗	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Oct 15, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q3 FY2023 May 16, 2023 10-Q ↗
Basic EPS, GAAP (USD)	$-0.38	$0.31	$-0.02	$2.38	$-1.35	$-0.05	$-0.01	$-0.04	$-0.05	$-0.01	—	—
Free Cash Flow per Share (USD)	$-0.19	$-0.02	$-0.03	—	$-3.33	$-0.04	$-0.00	—	$-0.05	—	—	—
Book Value per Share (USD)	$6.66	$0.44	$0.14	$0.17	$4.03	$0.03	$0.01	$0.08	$-0.02	$0.01	$0.01	—
Tangible Book Value per Share (USD)	$6.66	$0.44	$0.14	$0.17	$4.03	$0.03	$0.01	$0.08	$-0.02	$0.01	$0.01	—
Basic Weighted Avg Shares (shares)	1.28M	21.64M	21.64M	—	1.02M	20.00M	20.00M	—	20.00M	20.00M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q3 FY2026 Mar 31, 2026 10-Q ↗	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Oct 15, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q3 FY2023 May 16, 2023 10-Q ↗
Working Capital (USD)	$9.10M	$9.48M	$2.80M	$3.14M	—	—	—	$318.65K	—	—	—	—
Total Equity (USD)	$9.21M	$9.48M	$3.00M	$3.48M	$4.13M	$619.03K	$1.09M	$1.66M	$-497.80K	$196.84K	$1.31M	—

📋 What is driving earnings? 3 metrics

Metric	Q3 FY2026 Mar 31, 2026 10-Q ↗	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Oct 15, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q3 FY2023 May 16, 2023 10-Q ↗
Depreciation Expense (USD)	$9.33K	$14.46K	$47.99K	$156.87K	$22.51K	$21.98K	$67.29K	$120.48K	$51.11K	$57.90K	—	—
Net Income, GAAP (USD)	$-488.94K	$6.86M	$-386.90K	$-701.61K	$-1.38M	$-907.90K	$-265.58K	$-809.39K	$-1.06M	$-145.34K	—	—
Operating Cash Flow (USD)	$-239.78K	$-513.56K	$-610.34K	$-1.54M	$-3.41M	$-841.84K	$-29.68K	$-475.83K	$-1.07M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 3 years · 12 quarters

Advanced Biomed Inc.

Analytical Summary

12-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ADVB with peers